Spinal Cord Stimulation companies had a strong start in Q421 but the market lost steam as the Omicron variant surged

Despite a strong start for all SCS competitors in Q421, the SCS market started to run out of steam late in the quarter as the contagious Omicron variant surged around the world, slowing elective procedures and resulting in a YoY low-single-digit decrease in SCS revenue in both the US and WW.  For the full year (FY), US and WW SCS revenues were up in the low-double-digits driven by strong YoY results in Q121 and Q221 in which COVID trends improved against easy comps in Q120 and Q220. 

Among the many topics covered in detail in our comprehensive Q421/FY21 Spinal Cord Stimulation Market Recap* are:

SmartTRAK examines recent trends in breast implants and discusses their future impact on breast matrices.

Breast matrices, whether acellular dermal matrices (ADMs) or biosynthetics, have enabled improved outcomes in implant-based breast reconstruction and have contributed, in large part, to the revival of the prepectoral breast reconstruction technique. As the number of breast implant procedures has grown, so has the use of breast matrices. However, SmartTRAK believes the side effects and health consequences now associated with breast implants, while rare, will negatively impact breast implant usage and thus reduce the growth rate of breast matrices in 2022 and beyond.

In this informative Outlook article by Doug Devens, SmartTRAK's Product Director and Senior Editor, Wound, Doug covers:

• The Relationship between Breast Surgery and ADM Usage
• Trends in Implant Usage
• Recent Concerns that May Affect Breast Implant Usage
• The Future Outlook for 2022 and Beyond

We are pleased to announce that Beth Roach has joined the team at SmartTRAK as our new Account Manager, Customer Success. The SmartTRAK Customer Success team ensures that our users are realizing the maximum benefit from the platform. The team is a central point of contact for users, in addition to the existing SmartTRAK Sales and Analyst teams, and provides complimentary training (refresher or new user) in person or via video.

If you'd like to discuss your SmartTRAK account with Beth, please reach out to her and she'll be happy to support you.

Meet Beth Roach:

What is your role with SmartTRAK? Account Manager, Customer Success

What do you like about SmartTRAK? There is just so much information all in one place. All news, company profiles, market sizing, product portfolio comparison and so much more all at your fingertips!

Kathleen “Kathy” Schaum, President of Kathleen D. Schaum & Associates, discusses her thoughts on the impact of COVID-19 on wound care and reimbursement.

Kathy is a “go-to” provider of wound care reimbursement information, education and strategy to manufacturers and providers. In this interview with SmartTRAK, Kathy shares her thoughts on the impact of COVID-19 on the delivery and reimbursement of wound care and the advancements in remote monitoring, diagnostics and sensors. To find out more, including Kathy’s take on skin substitute/CTP trends, click on the following video recorded live via Google Meet (25:13 min). Specific interview topics by time code are outlined below. A link to the complete transcript of the interview is also provided below.

Procedures using surgical matrices continued their recovery and companies have resumed investing, with revenues surpassing their Q419 levels. 

As the pandemic wanes and procedures are again being scheduled, the US Surgical Matrices market grew strongly in Q421, gaining +12.7% YoY according to the SmartTRAK Financial Dashboard. AbbVie continued to lead the Surgical Matrices market, with Becton Dickinson also growing well ...

Among the many topics covered in detail in our comprehensive Q421 US Surgical Matrices Market Recap* are:

In this article, SmartTRAK reviews the development of AI in healthcare and profiles four companies implementing AI-driven imaging in these spaces.

The US Orthopedic Computer-Assisted Surgery (CAS) Market is one of the fastest-growing markets in orthopedics and is expected to reach revenues of $1.14B by 2025, according to SmartTRAK estimates. The Orthopedic CAS market includes a range of enabling technologies including robotic platforms, navigation systems, surgical planning tools, augmented/virtual reality technology and artificial intelligence (AI). AI is being increasingly incorporated into diagnostics and planning to assist in optimization of surgical decision making and anomaly detection.
 
The prominence of AI and machine learning technologies in medicine has snowballed over the past decade. Diagnostic Imaging and navigation is experiencing a new paradigm of technology through the emergence of AI-driven 3D reconstruction, segmentation and navigation applications. Two areas seeing quick implementation and adoption of these new systems are orthopedic planning/navigation and neurovascular diagnostics. In this article, SmartTRAK reviews the development of AI in healthcare and profiles four companies implementing AI-driven imaging in these spaces.

Abbott’s Allen Burton, MD discusses the Company’s new MRI labeling, expanded payer coverage for DRG, big data and digital initiatives in an interview with SmartTRAK at NANS 2022

Allen Burton, MD, Abbott Divisional Vice President, Medical Director Neuromodulation, discusses Abbott’s latest research and innovation in an interview with SmartTRAK at the North American Neuromodulation Society (NANS) Annual Meeting held January 13-14, 2022.

To find out more, including about the Company’s new MRI labeling, UnitedHealthCare coverage for DRG, big data and the status of Abbott’s digital initiatives, click on the video below to listen to the interview recorded live at NANS 2022. (30:18 min.) A link to download a complete transcript of the interview is also provided below.

Medtronic Neuromodulation executives Dave Anderson and Charlie Covert discuss the Company and the future of neuromodulation in an interview with SmartTRAK at NANS 2022

Dave Anderson, Medtronic’s President Neuromodulation, and Charlie Covert, Vice President and General Manager of Pain Therapies, discuss the Company, pandemic and the future of neuromodulation in a wide-ranging interview with SmartTRAK at the North American Neuromodulation Society (NANS) 25^th Annual Meeting held January 12-15, 2022 in Orlando, Florida.

To find out more about the Company’s newest innovations, expanding indications*, clinical research and strategies for driving growth in spinal cord stimulation (SCS) and deep brain stimulation (DBS), click on the following video recorded live at NANS 2022. (33:45 minutes.) Specific interview topics by time code are also outlined below. To download a complete transcript of the interview, click here.

D. Keith Grossman, chairman, CEO and president of Nevro Corporation, discusses the Company, expanding indications and driving growth through innovation and evidence in an interview with SmartTRAK

Nevro’s Keith Grossman expects randomized controlled trials and recent FDA approvals for expanded indications--painful diabetic neuropathy (PDN) and non-surgical refractory back pain (NSRBP)--to provide a competitive edge and help drive growth in the market for spinal cord stimulation (SCS). To find out more, including Grossman’s take on Medtronic’s recent FDA approval for the diabetic peripheral neuropathy (DPN) indication, click on the following video recorded live* via Google Meet (40:20 min). Specific interview topics by time code are also outlined below. If you would like to download a complete transcript of the interview, please click here.

SmartTRAK highlights current and emerging trends in hernia outcomes research presented at the European Hernia Society – Americas Hernia Society Joint Congress held in Copenhagen.

by Doug Devens - Sr Analyst, Biosurgery, IT Product Director

Changes in hernia regulations and evolving views on how to study the performance of hernia matrices have fueled a growing interest among hernia researchers in using different methods and data sources to measure outcomes associated with these devices. In this article, SmartTRAK highlights current and emerging trends in hernia outcomes research presented at the European Hernia Society – Americas Hernia Society Joint Congress (Hernia2021), in Copenhagen, including the increasing use of registries and their relative advantages and disadvantages compared to the gold standard randomized controlled trial (RCT). ­